Gynecologic Oncology | Specialty

Dr Grisham on the Safety of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

April 4th 2025

Rachel N. Grisham, MD, discusses the safety of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Tisotumab Vedotin Earns European Approval for Pretreated Recurrent/Metastatic Cervical Cancer

April 1st 2025

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer

March 31st 2025

Yong Jae Lee, MD, PhD, discusses key efficacy outcomes with nivolumab monotherapy in completely surgically resectable dMMR endometrial cancer.

Dr Duska on the Efficacy of Pembrolizumab Plus Concurrent CRT in Advanced Cervical Cancer

March 31st 2025

Linda R. Duska, MD, MPH, discusses OS and PFS2 outcomes with concurrent pembrolizumab and chemoradiotherapy in high-risk advanced cervical cancer.

Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer

March 28th 2025

Chunyan Lan, MD, PhD, discusses data with cadonilimab plus lenvatinib in advanced endometrial cancer, as well as next steps for evaluating the combination.

Ongoing Research to Watch in Advanced Endometrial Cancer in 2025

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss ongoing research to watch in endometrial cancer.

ADCs and Novel Agents Under Investigation in Advanced Endometrial Cancer

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss antibody-drug conjugates and agents under evaluation in endometrial cancer.

Subgroup Data for Lenvatinib/Pembrolizumab In Frontline Advanced Endometrial Cancer After Perioperative Chemo

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss subgroup data for frontline lenvatinib/pembrolizumab in endometrial cancer after perioperative chemotherapy.

The Role of IO/Chemo Combinations in Frontline Advanced/Recurrent Endometrial Cancer

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline chemoimmunotherapy combinations in advanced endometrial cancer.

LEAP-001 Data for First-Line Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.

Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer

March 27th 2025

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer

March 27th 2025

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer

March 26th 2025

Current Treatment Strategies and Challenges in Frontline Advanced Endometrial Cancer

March 26th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline treatment trends and challenges in advanced endometrial cancer.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 3/16

March 22nd 2025

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Emerging ADCs, Biomarker-Driven Treatments, and Diagnostic Advancements Take Center Stage at the SGO Annual Meeting

March 21st 2025

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends in gynecologic cancer care discussed during the 2025 SGO Annual Meeting.

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

March 18th 2025

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer

March 18th 2025

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.